Limits...
BioBanking as the central tool for translational medicine CTM issue 2013.

Marko-Varga G - Clin Transl Med (2013)

Bottom Line: Currently, companion diagnostics is at the core of the personalized medicine paradigm shift.It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent.It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations.

View Article: PubMed Central - HTML - PubMed

Affiliation: Clinical Protein Science & Imaging, Biomedical Center, Department of Measurement Technology and Industrial Electrical Engineering, Lund University, BMC C13, Lund, 221 84, Sweden. gyorgy.marko-varga@elmat.lth.se.

ABSTRACT
THE IMPACT OF MAPPING THE HUMAN PROTEOME: Globally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments. Hospitals worldwide strive to seek the best cure for patients, suffering from various diseases. A consequence of these global changes, of healthy populations in relation to patients forms the basis for the build of large and centralized biobank facilities, with strategies where the search for an understanding of diseases at a molecular level is at heart. The efforts made lies within large governmental resource allocations where patient centers are collecting samples from clinical study participants in order to try to discover universal expression patterns and molecular signatures of disease and disease stages. Most developments in this area are aimed towards the discovery, and understanding diagnosis implementations. By providing the right treatment alternatives for patients care, at the right time point i.e., at a given disease stage development becomes a major goal where pharmaceutical industry, academia and the health care sector joins forces in large clinical epidemiological, population-, and disease based studies. This becomes a clear strategic link to the enhancement and prospects for personalized medicines and target directed diagnosis developments (Companion Diagnostics), which require coordinated efforts across a wide range of disciplines. Currently, companion diagnostics is at the core of the personalized medicine paradigm shift. It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent. It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations.

No MeSH data available.


Related in: MedlinePlus

Biobank work flow where large scale Biobanks are utilized for high-throughput protein sequencing using mass spectrometry platforms.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3585702&req=5

Figure 2: Biobank work flow where large scale Biobanks are utilized for high-throughput protein sequencing using mass spectrometry platforms.

Mentions: Blood fractions from patients comprising whole blood, serum, plasma (EDTA, citrate, and heparin) are being stored and processed by automated processing in -80C storage units. High-density sample tube systems are applied to maximize the sample output per patient utilizing 384-rack systems[7]. Bar code assignments ensure the uniqueness of each and every sample that is used within the analysis process generating both MS-MS and antibody read-outs. The workflow and processing of Biobank samples to generate extensive protein sequence information in health and disease is outlined in Figure2.


BioBanking as the central tool for translational medicine CTM issue 2013.

Marko-Varga G - Clin Transl Med (2013)

Biobank work flow where large scale Biobanks are utilized for high-throughput protein sequencing using mass spectrometry platforms.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3585702&req=5

Figure 2: Biobank work flow where large scale Biobanks are utilized for high-throughput protein sequencing using mass spectrometry platforms.
Mentions: Blood fractions from patients comprising whole blood, serum, plasma (EDTA, citrate, and heparin) are being stored and processed by automated processing in -80C storage units. High-density sample tube systems are applied to maximize the sample output per patient utilizing 384-rack systems[7]. Bar code assignments ensure the uniqueness of each and every sample that is used within the analysis process generating both MS-MS and antibody read-outs. The workflow and processing of Biobank samples to generate extensive protein sequence information in health and disease is outlined in Figure2.

Bottom Line: Currently, companion diagnostics is at the core of the personalized medicine paradigm shift.It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent.It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations.

View Article: PubMed Central - HTML - PubMed

Affiliation: Clinical Protein Science & Imaging, Biomedical Center, Department of Measurement Technology and Industrial Electrical Engineering, Lund University, BMC C13, Lund, 221 84, Sweden. gyorgy.marko-varga@elmat.lth.se.

ABSTRACT
THE IMPACT OF MAPPING THE HUMAN PROTEOME: Globally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments. Hospitals worldwide strive to seek the best cure for patients, suffering from various diseases. A consequence of these global changes, of healthy populations in relation to patients forms the basis for the build of large and centralized biobank facilities, with strategies where the search for an understanding of diseases at a molecular level is at heart. The efforts made lies within large governmental resource allocations where patient centers are collecting samples from clinical study participants in order to try to discover universal expression patterns and molecular signatures of disease and disease stages. Most developments in this area are aimed towards the discovery, and understanding diagnosis implementations. By providing the right treatment alternatives for patients care, at the right time point i.e., at a given disease stage development becomes a major goal where pharmaceutical industry, academia and the health care sector joins forces in large clinical epidemiological, population-, and disease based studies. This becomes a clear strategic link to the enhancement and prospects for personalized medicines and target directed diagnosis developments (Companion Diagnostics), which require coordinated efforts across a wide range of disciplines. Currently, companion diagnostics is at the core of the personalized medicine paradigm shift. It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent. It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations.

No MeSH data available.


Related in: MedlinePlus